Equities research analysts at StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a report issued on Thursday. The brokerage set a “sell” rating on the stock.
Navidea Biopharmaceuticals Stock Performance
NYSE:NAVB opened at $0.04 on Thursday. Navidea Biopharmaceuticals has a 1 year low of $0.02 and a 1 year high of $0.33. The firm has a 50 day moving average of $0.04 and a 200-day moving average of $0.06. The stock has a market capitalization of $3.65 million, a P/E ratio of -0.61 and a beta of 1.14.
Institutional Trading of Navidea Biopharmaceuticals
A hedge fund recently raised its stake in Navidea Biopharmaceuticals stock. Renaissance Technologies LLC lifted its stake in Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) by 264.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 238,133 shares of the company’s stock after purchasing an additional 172,800 shares during the period. Renaissance Technologies LLC owned 0.74% of Navidea Biopharmaceuticals worth $62,000 at the end of the most recent quarter. 0.01% of the stock is currently owned by institutional investors and hedge funds.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
Further Reading
- Five stocks we like better than Navidea Biopharmaceuticals
- There Are Different Types of Stock To Invest In
- 3 Value Stocks Too Small For Buffett’s Portfolio
- What is Put Option Volume?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What is a Stock Market Index and How Do You Use Them?
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
